FrancophonIA/ELRC3.0 huggingface dataset:
English: The material will also provide the available evidence regarding the safety and efficacy of ponatinib when dose is reduced in patients with chronic phase CML who have achieved major cytogenetic response.
Estonian: Teabematerjal sisaldab ka ponatiniibi ohutuse ja efektiivsuse olemasolevaid andmeid seoses annuse vähendamisega kroonilises faasis CML-iga patsientidel, kellel on tekkinud oluline tsütogeneetiline ravivastus.
English: Iclusig is authorised for use in patients with chronic myeloid leukaemia (CML) and acute lymphoblastic leukaemia (ALL) who cannot take or tolerate several other medicines of the same class (known as ‘tyrosine-kinase inhibitors').
Estonian: Iclusig on näidustatud kroonilise müeloidse leukeemia (CML) ja ägeda lümfoblastse leukeemiaga (ALL) patsientide raviks, kellele ei sobi mitu muud sama klassi ravimit (türosiinkinaasiinhibiitorid) või kes neid ei talu.
English: The company that markets Iclusig will provide healthcare professionals with educational material highlighting important risks for which monitoring and/or dose adjustments are recommended and including available data on the relationship between dose of Iclusig and risk of blood vessel blockage.
Estonian: Iclusigit turustav ettevõte annab tervishoiutöötajatele teabematerjali, milles on kirjeldatakse olulisi riske, mille korral soovitatakse patsientide jälgimist ja/või annuse kohandamist; samuti on teabematerjalis Iclusigi annuse ja veresoonte sulguse riski seose olemasolev teave.
English: The product information will be updated with strengthened warnings about the risks with Iclusig, and to also provide healthcare professionals with the latest evidence in case they wish to consider reducing the dose of Iclusig in patients with ‘chronic phase' CML who are responding well to treatment, and who might be at particular risk of blood vessel blockage.
Estonian: Ravimiteabes on Iclusigiga kaasnevate riskide hoiatusi tugevdatud ja tervishoiutöötajatele on antud ajakohased andmed juhuks, kui nad soovivad kaaluda Iclusigi annuse vähendamist kroonilises faasis CML-iga patsientidel, kelle ravivastus on hea ja kellel on eriti suur veresoonte sulguse risk.
English: The active substance in Iclusig, ponatinib, belongs to a group of medicines called ‘tyrosine-kinase inhibitors'.
Estonian: Iclusigi toimeaine ponatiniib kuulub türosiinkinaasiinhibiitorite ravimirühma.
English: A study on the safety and benefits of Iclusig is also planned, to help clarify if lower doses of the medicine would carry a lower risk of blood clots or blockages of the blood vessels while still having a beneficial effect in patients with chronic phase CML.
Estonian: Kavandatakse ka Iclusigi ohutuse ja kasulikkuse uuringut, et selgitada, kas ravimi väiksemate annuste korral on kroonilises faasis CML-iga patsientidel veresoonte trombide või sulguste risk väiksem ja kasulik toime siiski olemas.
English: During its review, the PRAC assessed available data on the nature, frequency and severity of blood clots or blockage of the arteries or veins and considered the potential mechanism for these side effects.
Estonian: Kõigepealt vaatas Iclusigi ravimiteabe läbi EMA ravimiohutuse järelevalve riskihindamiskomitee, hinnates arterite või veenide trombide või sulguste olemuse, sageduse ja raskuse olemasolevaid andmeid ning uuris nende kõrvalnähtude võimalikku tekkemehhanismi.
English: • Iclusig is a medicine used for the treatment of leukaemia, a type of cancer that affects white blood cells.
Estonian: • Iclusig on ravim, mida kasutatakse leukeemia raviks (leukeemia on leukotsüütide ehk vere valgeliblede teatud vähiliik).
English: The PRAC also sought the advice of a group of experts in oncology before finalising its recommendations, which have now been endorsed by the Agency's Committee for Medicinal Products for Human Use (CHMP) in its final opinion.
Estonian: Enne lõplike soovituste andmist küsis riskihindamiskomitee nõu onkoloogia eksperdirühmalt.
English: The CHMP opinion will now be forwarded to the European Commission, which will issue a final decision in due course.
Estonian: Inimravimite komitee arvamus edastati Euroopa Komisjonile, kes tegi 15. jaanuaril 2015 õiguslikult siduva lõpliku otsuse, mis kehtib kogu Euroopa Liidus.
English: Treatment is continued until the patient no longer benefits from it or side effects become unacceptable.
Estonian: Ravi jätkatakse, kuni patsient ei saa enam sellest kasu või kui kõrvalnähud muutuvad vastuvõetamatuteks.
English: Patients should not eat for at least two hours before and one hour after their dose of Cometriq.
Estonian: Patsiendid ei tohi süüa vähemalt kaks tundi enne ja üks tund pärast Cometriqi võtmist.
English: However, the Committee noted that many patients required reductions in their dose and recommended that the company should study whether starting at lower doses would still be effective but would have fewer side effects.
Estonian: Inimravimite komitee märkis siiski, et paljudel patsientidel oli vaja annust vähendada, ja soovitas ettevõttel uurida, kas ravi alustamine väiksemate annustega oleks siiski efektiivne, kuid vähemate kõrvalnähtudega.
English: A risk management plan has been developed to ensure that Cometriq is used as safely as possible.
Estonian: Töötati välja riskijuhtimiskava, et tagada Cometriqi võimalikult ohutu kasutamine.
English: The side effects were considered manageable and were acceptable, compared with the limited other treatment options available.
Estonian: Kõrvalnähte peeti ravitavateks ja need olid võrreldes muude piiratud olemasolevate ravivõimalustega vastuvõetavad.
English: What measures are being taken to ensure the safe and effective use of Cometriq?
Estonian: Mis meetmed võetakse, et tagada Cometriqi ohutu ja efektiivne kasutamine?
English: Cometriq cabozantinib
Estonian: Cometriq kabosantiniib
English: The European Commission granted a marketing authorisation valid throughout the European Union for Cometriq on 21 March 2014.
Estonian: Euroopa Komisjon andis Cometriqi müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 21. märtsil
English: The recommended dose is 140 mg once a day, taken as one 80-mg and three 20-mg capsules.
Estonian: Soovitatav annus on 140 mg üks kord ööpäevas, mida võetakse ühe 80 mg ja kolme 20 mg kapslina.
English: By blocking the activity of these receptors in cancer cells, the medicine reduces the growth and spread of the cancer.
Estonian: Nende retseptorite aktiivsuse blokeerimisel vähirakkudes vähendab ravim vähi kasvu ja levikut.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) decided that Cometriq's benefits are greater than its risks and recommended that it be approved for use in the EU.
Estonian: Inimravimite komitee otsustas, et Cometriqi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
English: Cometriq is available as capsules (20 and 80 mg).
Estonian: Cometriqi turustatakse kapslitena (20 mg ja 80 mg).
English: 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom due to side effects, especially during the first eight weeks of therapy.
Estonian: 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
English: The main measure of effectiveness was progression-free survival (how long the patients lived before their disease got worse): in patients given Cometriq this was 11.2 months, compared with 4.0 months in those given placebo.
Estonian: Efektiivsuse põhinäitaja oli progressioonivaba elulemus (aeg haiguse süvenemiseni): Cometriqi saanud patsientidel oli see 11,2 kuud võrreldes 4,0 kuuga platseebot saanud patsientidel.
English: Cometriq was given once a day in an initial dose of 140 mg (reduced if necessary due to side effects) and compared with placebo (a dummy treatment).
Estonian: Cometriqi anti üks kord ööpäevas algannuses 140 mg (vajaduse korral vähendati annust kõrvalnähtude tõttu) ja võrreldi platseeboga (näiva ravimiga).
English: The summary of the opinion of the Committee for Orphan Medicinal Products for Cometriq can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
Estonian: Harvikravimite komitee arvamuse kokkuvõte Cometriqi kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
English: Since Cometriq has been granted a conditional approval, the company that markets Cometriq will provide information from a study comparing the safety and effectiveness of different doses of Cometriq, and its benefit in patients lacking the RET gene mutation or whose cancer has changes in another family of genes called RAS.
Estonian: Et Cometriq kiideti heaks tingimuslikult, esitab Cometriqi turustav ettevõte teabe uuringust, mis võrdleb Cometriqi erinevate annuste ohutust ja efektiivsust ning selle kasulikkust patsientidel, kellel puudub RET-geeni mutatsioon või kelle vähil esinevad muutused teises, RAS-geenide perekonnas.
English: The full EPAR and risk management plan summary for Cometriq can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst ja riskijuhtimiskava kokkuvõte Cometriqi kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: The benefits of Cometriq may be smaller for patients whose cancer does not have a mutation in a gene called the ‘re-arranged during transfection' (RET) gene, and this should be taken into account when deciding whether to start treatment.
Estonian: Cometriqi kasulikkus võib olla väiksem patsientidel, kelle vähil ei ole RET-geeni (transfektsiooni ajal ümberkorraldunud geeni) mutatsiooni, ning seda tuleb ravi alustamise otsustamisel arvesse võtta.
English: What is Cometriq and what is it used for?
Estonian: Mis on Cometriq ja milleks seda kasutatakse?
English: This is a summary of the European public assessment report (EPAR) for Cometriq.
Estonian: See on ravimi Cometriq Euroopa avaliku hindamisaruande kokkuvõte.
English: Other information about Cometriq
Estonian: Muu teave Cometriqi kohta
English: Cometriq should be used with care in patients taking certain other medicines that affect the way it is broken down in the body.
Estonian: Cometriqi tuleb kasutada ettevaatlikult patsientidel, kes võtavad teatud teisi ravimeid, mis mõjutavad Cometriqi lagunemist organismis.
English: Cometriq is used when the cancer cannot be removed by surgery and has progressed or spread to other parts of the body.
Estonian: Cometriqi kasutatakse juhul, kui vähki ei saa kirurgiliselt eemaldada ja see on progresseerunud või levinud organismis ka mujale.
English: These enzymes can be found in certain receptors (such as VEGF, MET and RET receptors) in cancer cells, where they activate several processes including cell division and the growth of new blood vessels to supply the cancer.
Estonian: Neid ensüüme leidub vähirakkude teatud retseptorites (nt VEGF-, MET- ja RET-retseptorid), kus nad aktiveerivad mitmeid protsesse, sh rakkude jagunemist ja uute veresoonte kasvu vähi verevarustuse tagamiseks.
English: Why is Cometriq approved?
Estonian: Miks Cometriq heaks kiideti?
English: It is not intended to provide practical advice on how to use Cometriq.
Estonian: Hindamisaruandes ei anta Cometriqi kasutamise praktilisi nõuandeid.
English: Because the number of patients with medullary thyroid cancer is low, the disease is considered ‘rare', and Cometriq was designated an ‘orphan medicine' (a medicine used in rare diseases) on 6 February
Estonian: Et medullaarse kilpnäärmevähiga patsientide arv on väike ja see haigus esineb harva, nimetati Cometriq 6. veebruaril 2009 harvikravimiks.
English: Cometriq has been shown to be effective in one main study involving 330 adults with medullary thyroid cancer that could not be treated with surgery and was extensive or had spread to other parts of the body.
Estonian: Cometriqi efektiivsust tõendati ühes põhiuuringus, milles osales 330 täiskasvanut, kellel oli medullaarne kilpnäärmevähk, mida ei olnud võimalik ravida kirurgiliselt ja mis oli ulatuslik või levinud teistesse kehaosadesse.
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Cometriq, including the appropriate precautions to be followed by healthcare professionals and patients.
Estonian: Selle alusel lisati Cometriqi omaduste kokkuvõttesse ja pakendi infolehele ravimi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
English: What are the risks associated with Cometriq?
Estonian: Mis riskid Cometriqiga kaasnevad?
English: Cometriq can only be obtained with a prescription and treatment should only be started by a doctor who has experience in using cancer medicines.
Estonian: Cometriq on retseptiravim ja ravi peab alustama vähiravimite kasutamises kogenud arst.
English: What information is still awaited for Cometriq?
Estonian: Mis teavet Cometriqi kohta veel oodatakse?
English: Cometriq is a cancer medicine that contains the active substance cabozantinib.
Estonian: Cometriq on vähiravim, mis sisaldab toimeainet kabosantiniibi.
English: Cometriq had shown a benefit in patients with advanced medullary thyroid cancer unsuitable for surgery, who have few other treatment options.
Estonian: Cometriq on näidanud kasulikkust mitteopereeritava kaugelearenenud medullaarse kilpnäärmevähiga patsientidel, kellel on vähe muid ravivõimalusi.
English: For practical information about using Cometriq, patients should read the package leaflet or contact their doctor or pharmacist.
Estonian: Kui vajate Cometriqi kasutamise praktilisi nõuandeid, lugege pakendi infolehte või pöörduge oma arsti või apteekri poole.
English: The most common side effects with Cometriq (which may affect more than 2 in 10 people) are diarrhoea, palmar-plantar erythrodysaesthesia syndrome (hand-foot syndrome, which involves rash and numbness on the palms and soles), loss of weight, loss of appetite, nausea (feeling sick), tiredness, taste disturbances, changes in hair colour, hypertension (high blood pressure), inflammation of the mucosa (moist tissue that lines certain body cavities) including stomatitis (inflammation of the lining of the mouth), constipation, vomiting, weakness, and changes in the sound of the voice.
Estonian: Cometriqi kõige sagedamad kõrvalnähud (võivad esineda enam kui 2 patsiendil 10st) on kõhulahtisus, palmaarplantaarne erütrodüsesteesia sündroom (löövet ning tuimust tekitav käe- ja jalalabade nahareaktsioon), kehakaalu langus, isukaotus, iiveldus, väsimus, maitsehäired, juustevärvi muutused, hüpertensioon (kõrge vererõhk), limaskestade põletik, sealhulgas stomatiit (suu limaskesta põletik), kõhukinnisus, oksendamine, nõrkus ja häälemuutused.
English: For more information about treatment with Cometriq, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Cometriqiga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: It is used to treat adults with medullary thyroid cancer, a type of cancer originating in the cells in the thyroid gland that produce the hormone calcitonin.
Estonian: Seda kasutatakse täiskasvanute raviks, kellel on medullaarne kilpnäärmevähk (vähiliik, mis tekib kilpnäärme rakkudes, mis eritavad hormooni kaltsitoniini).
English: The most common abnormal results in laboratory blood tests were increased liver enzymes such as aspartate aminotransferase (AST), alanine aminotransferase (ALT) and alkaline phosphatase (ALP), low white cell counts (lymphopenia or neutropenia), thrombocytopenia (low blood-platelet counts), hypocalcaemia (low blood calcium levels), hypophosphataemia (low blood levels of phosphates), hypomagnesaemia (low blood magnesium levels), hypokalaemia (low blood potassium levels) and hyperbilirubinaemia (increased amounts of bilirubin, a breakdown product of red blood cells).
Estonian: Kõige tavalisemad kõrvalekalded laboratoorsete vereanalüüside tulemustes olid maksaensüümide, nagu aspartaataminotransferaasi (AST), alaniinaminotransferaasi (ALT) ja aluselise fosfataasi (ALP) sisalduse suurenemine, valgeliblede väike arv (lümfopeenia või neutropeenia), trombotsütopeenia (trombotsüütide e vereliistakute väike arv), hüpokaltseemia (vere väike kaltsiumisisaldus), hüpofosfateemia (vere väike fosfaadidisaldus), hüpomagneseemia (vere magneesiumivaegus), hüpokaleemia (vere väike kaaliumisisaldus) ja hüperbilirubineemia (suurenenud bilirubiinisisaldus, mis on punavereliblede lagusaadus).
English: How is Cometriq used?
Estonian: Kuidas Cometriqi kasutatakse?
English: Cometriq has been given ‘conditional approval'.
Estonian: Cometriqi müügiluba anti tingimuslikult.
English: For the full list of all side effects and restrictions with Cometriq, see the package leaflet.
Estonian: Cometriqi kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: How does Cometriq work?
Estonian: Kuidas Cometriq toimib?
English: The most common serious side effects are pneumonia, inflammation of the mucosa, hypocalcaemia (low calcium levels in the blood), dysphagia (difficulty swallowing), dehydration, pulmonary embolism (blood clots in the vessels supplying the lungs), and hypertension.
Estonian: Kõige sagedamad rasked kõrvalnähud on pneumoonia, limaskestapõletik, hüpokaltseemia (väike kaltsiumisisaldus veres), düsfaagia (neelamisraskused), dehüdratsioon, kopsuemboolia (verehüübed kopsuveresoontes) ja hüpertensioon.
English: The dose may need to be reduced or stopped temporarily
Estonian: Kõrvalnähtude tõttu võib olla vajalik annuse vähendamine või ravi ajutine peatamine, eriti esimese kaheksa ravinädala jooksul.
English: The active substance in Cometriq, cabozantinib, is a tyrosine kinase inhibitor.
Estonian: Cometriqi toimeaine kabosantiniib on türosiinkinaasiinhibiitor, mis blokeerib türosiinkinaasideks nimetatavate ensüümide toime.
English: What benefits of Cometriq have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Cometriqi kasulikkus?
English: Other beneficial effects on patients with regards to other system organ classes have not convincingly been shown.
Estonian: Teisi kasulikke mõjusid patsientidele seoses muude elundisüsteemide liikidega ei ole veenvalt tõendatud.
English: These non-fatal events are considered serious and life-threatening and may be associated with considerable morbidity.
Estonian: Neid mittesurmavaid juhtumeid peetakse raskeiks ja eluohtlikeks ning neid võib seostada märkimisväärse suremusega.
English: In the EU sibutramine was first authorised in January 1999.
Estonian: Sibutramiini müügiluba Euroopa Liidus anti esimest korda 1999. aasta jaanuaris.
English: For the suspension to be lifted the Marketing Authorisation Holders would need to provide the National Competent Authorities with the following:
Estonian: Peatamise lõpetamiseks peavad müügilubade hoidjad esitama pädevatele riiklikele asutustele järgmised andmed:
English: 04010 Campoverde di Aprilia Italy
Estonian: 04010 Campoverde di Aprilia Itaalia
English: Plaza CEIN 5, Nave B-14Noain (Navarra) Spain
Estonian: Plaza CEIN 5, Nave B-14Noain (Navarra) Hispaania
English: Abbott Laboratories Kft. Teve u. 1/a-c 1139 Budapest Hungary
Estonian: Abbott Laboratories Kft. Teve u. 1/a-c 1139 Budapest Ungari
English: Belgium Teva pharma belgium Laarstraat 16
Estonian: Teva pharma belgium Laarstraat 16
English: 2132 WT, Hoofddorp Netherlands
Estonian: 2132 WT, Hoofddorp Holland
English: An Article 31 referral was triggered in March 2002 due to safety concerns based on fatal adverse reactions.
Estonian: 2002. aasta märtsis alustati artikli 31 kohast menetlust ohutusprobleemide tõttu, mida põhjustasid surmaga lõppevad kõrvalnähud.
English: Rowex Ltd Bantry Co.Cork Ireland
Estonian: Rowex Ltd Bantry Co.Cork Iirimaa
English: OVERALL SUMMARY OF THE SCIENTIFIC EVALUATION OF SIBUTRAMINECONTAINING MEDICINAL PRODUCTS (SEE ANNEX I)
Estonian: SIBUTRAMIINI SISALDAVATE RAVIMITE (vt I lisa) TEADUSLIKU HINDAMISE ÜLDKOKKUVÕTE
English: In addition, the maintenance of weight loss after cessation of treatment is questionable.
Estonian: Samuti on küsitav kaaluvähenemise säilitamine pärast ravi lõpetamist.
English: The CHMP also requested a Scientific Advisory Group (SAG) Diabetes/Endocrinology meeting to be held in January to provide additional expert input.
Estonian: Inimravimite komitee palus ka diabeedi/endokrinoloogia teadusnõuanderühmal korraldada jaanuaris koosolek, et pakkuda täiendavat eksperdiarvamust.
English: Eastbourne, East Sussex BN22 9AG United Kingdom
Estonian: Eastbourne, East Sussex BN22 9AG Suurbritannia
English: 2031 GA, Haarlem Netherlands
Estonian: 2031 GA, Haarlem Holland
English: 94528 RUNGIS CEDEX FRANCE
Estonian: 94528 RUNGIS CEDEX Prantsusmaa
English: 83602 Holzkirchen Germany
Estonian: 83602 Holzkirchen Saksamaa
English: Even in this “best case scenario” approximately 1400 patients would need to be treated with sibutramine to prevent one CV event.
Estonian: Isegi sellise parima stsenaariumi korral tuleks sibutramiiniga ravida ligikaudu 1400 patsienti, et ennetada üht kardiovaskulaarhaiguse juhtu.
English: Veluwezoom 22 1327 AH, Almere Netherlands
Estonian: Veluwezoom 22 1327 AH, Almere Holland
English: S.C. TERAPIA S.A. Str. Fabricii, nr. 124, Cluj-Napoca, Romania
Estonian: S.C. TERAPIA S.A. Str. Fabricii, nr. 124, Cluj-Napoca, Rumeenia
English: DK-1100 København K Denmark
Estonian: DK-1100 København K Taani
English: Edvard Thomsens Vej 14 2300 København S Danmark
Estonian: Edvard Thomsens Vej 14 2300 København S Taani
English: The Sibutramine Cardiovascular OUTcomes (SCOUT) study was initiated in January
Estonian: Sibutramiini toime uuringut kardiovaskulaarsete ravitulemuste suhtes (SCOUT) alustati 2003. aasta jaanuaris.
English: The CHMP also recommended that temporary measures are needed and therefore recommends to the European Commission that the marketing and use of sibutramine-containing medicinal products be suspended forthwith in all concerned EU Member States awaiting the adoption of the final measures.
Estonian: Komitee soovitas ka võtta rahvatervise kaitsmiseks ajutisi meetmeid ning soovitas seepärast Euroopa Komisjonil peatada sibutramiini sisaldavate ravimite turustamine ja kasutamine kõikides asjaomastes Euroopa Liidu liikmesriikides kuni lõplike meetmete võtmiseni.
English: Belgium Sandoz NV Telecom Gardens Medialaan 40
Estonian: Sandoz NV Telecom Gardens Medialaan 40
English: 1A Farma A/S Herstedøstervej 27-29 DK-2620 Albertslund Denmark
Estonian: 1A Farma A/S Herstedøstervej 27-29 DK-2620 Albertslund Taani
English: Abbot Laboratories Ireland Ltd 4051 Kingswood Drive Citywest Business Campus Dublin 24
Estonian: Abbott Laboratories Ireland Ltd 4051 Kingswood Drive Citywest Business Campus Dublin 24
English: The current use of sibutramine is already substantially restricted by the SPC and no further useful or practical restrictions were identified.
Estonian: Sibutramiini praegune kasutus on juba ravimi omaduste kokkuvõttes oluliselt piiratud ega ole tuvastatud täiendavaid kasulikke või otstarbekaid piiranguid.
English: Dolenjska c. 242c SI-1000 Ljubljana Slovenia
Estonian: Dolenjska c. 242c SI-1000 Ljubljana Sloveenia
English: In addition, it was not possible, based on the SCOUT data and other published or unpublished studies, to identify patient groups that may derive benefit from sibutramine use without an increased cardiovascular risk.
Estonian: Pealegi ei olnud uuringu SCOUT ja muude avaldatud või avaldamata uuringute andmete põhjal võimalik tuvastada patsiendirühmi, kes võiksid saada sibutramiinist kasu, ilma et suureneks kardiovaskulaarhaiguste risk.
English: 1800 Vilvoorde
Estonian: 1800 Vilvoorde Belgia
English: ANNEX I LIST OF THE INVENTED NAME, PHARMACEUTICAL FORM, STRENGTHS OF THE MEDICINAL PRODUCTS, ROUTE OF ADMINISTRATION AND MARKETING AUTHORISATION HOLDERS IN THE MEMBER STATES (EU/EEA)
Estonian: I LISA RAVIMITE NIMETUSTE, RAVIMVORMIDE, TUGEVUSTE, MANUSTAMISVIISIDE, MÜÜGILOA HOIDJATE LOETELU LIIKMESRIIKIDES